Free Trial
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CryoPort, Inc. stock logo
CYRX
CryoPort
$16.83
+1.1%		$16.38
$7.61
▼
$18.36
$852.85M1.96599,894 shs147,664 shs
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
$11.42
-1.0%		$8.71
$5.37
▼
$18.22
$770.37M1.791.42 million shs856,974 shs
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
$127.86
+1.3%		$124.40
$69.51
▼
$144.35
$714.97M1.06144,297 shs37,990 shs
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
$2.05
-5.3%		$1.16
$0.84
▼
$4.31
$261.24M0.731.41 million shs4.00 million shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CryoPort, Inc. stock logo
CYRX
CryoPort
-1.83%-4.09%+4.26%+0.91%+78.54%
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
-1.75%+0.47%+64.31%+40.14%-17.85%
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
-1.10%-2.92%+3.85%+26.87%+76.50%
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
+5.37%+10.20%+138.33%+31.71%+129.67%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CryoPort, Inc. stock logo
CYRX
CryoPort
$16.83
+1.1%		$16.38
$7.61
▼
$18.36
$852.85M1.96599,894 shs147,664 shs
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
$11.42
-1.0%		$8.71
$5.37
▼
$18.22
$770.37M1.791.42 million shs856,974 shs
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
$127.86
+1.3%		$124.40
$69.51
▼
$144.35
$714.97M1.06144,297 shs37,990 shs
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
$2.05
-5.3%		$1.16
$0.84
▼
$4.31
$261.24M0.731.41 million shs4.00 million shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CryoPort, Inc. stock logo
CYRX
CryoPort
-1.83%-4.09%+4.26%+0.91%+78.54%
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
-1.75%+0.47%+64.31%+40.14%-17.85%
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
-1.10%-2.92%+3.85%+26.87%+76.50%
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
+5.37%+10.20%+138.33%+31.71%+129.67%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CryoPort, Inc. stock logo
CYRX
CryoPort
2.80
Moderate Buy$19.3314.91% Upside
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
1.50
Reduce$7.00-38.68% Downside
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
2.00
Hold$110.00-13.97% Downside
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
2.60
Moderate Buy$3.8387.45% Upside

Current Analyst Ratings Breakdown

Latest NAUT, CYRX, DNA, and MLAB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/13/2026
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetHold$9.00 ➝ $11.00
10/13/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
Robert W. Baird logo
Robert W. Baird
Subscribe to MarketBeat All Access to unlock brokerage rankings
Set Price Target$26.00
10/13/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeBuy
10/13/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$25.00 ➝ $26.00
10/8/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (D) ➝ Hold (C-)
10/8/2026
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeHold (C-) ➝ Hold (C)
10/1/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$16.00 ➝ $19.00
9/30/2026
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeHold
9/29/2026
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
Roth Capital logo
Roth Capital
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageBuy$3.50
9/29/2026
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
Roth Capital logo
Roth Capital
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeStrong-Buy
9/18/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$25.00
(Data available from 10/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CryoPort, Inc. stock logo
CYRX
CryoPort
$176.18M4.84N/AN/A$9.19 per share1.83
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
$170.15M4.52N/AN/A$8.74 per share1.31
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
$249.73M2.87$11.81 per share10.83$33.71 per share3.79
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
N/AN/AN/AN/A$1.24 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CryoPort, Inc. stock logo
CYRX
CryoPort
$78.30M-$0.90N/AN/AN/A-20.05%-7.20%-4.30%11/3/2026 (Estimated)
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
-$312.76M-$5.01N/AN/AN/A-259.96%-60.27%-26.88%11/5/2026 (Estimated)
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
$6.71M$0.84152.10N/AN/A1.92%22.72%9.82%11/5/2026 (Estimated)
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
-$59M-$0.45N/AN/AN/AN/A-37.58%-30.83%10/26/2026 (Estimated)

Latest NAUT, CYRX, DNA, and MLAB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
-$0.58N/AN/AN/A$21.50 millionN/A
11/5/2026Q2 2027
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
$2.29N/AN/AN/A$62.20 millionN/A
11/3/2026Q3 2026
CryoPort, Inc. stock logo
CYRX
CryoPort
-$0.19N/AN/AN/A$48.69 millionN/A
10/26/2026Q3 2026
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
-$0.14N/AN/AN/A$0.21 millionN/A
8/10/2026Q1 2027
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
N/A$2.68N/A$0.49N/A$60.14 million
8/6/2026Q2 2026
CryoPort, Inc. stock logo
CYRX
CryoPort
-$0.1933-$0.20-$0.0067-$0.20$48.18 million$48.97 million
8/5/2026Q2 2026
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
-$0.8950-$0.75+$0.1450-$0.75$24.05 million$20.16 million
7/27/2026Q2 2026
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
-$0.1350-$0.11+$0.0250-$0.11$0.10 million$0.19 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CryoPort, Inc. stock logo
CYRX
CryoPort
N/AN/AN/AN/AN/A
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
N/AN/AN/AN/AN/A
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
$0.640.50%N/A76.19%N/A
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
N/AN/AN/AN/AN/A

Latest NAUT, CYRX, DNA, and MLAB Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/8/2026
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
quarterly$0.160.5%11/30/202611/30/202612/15/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CryoPort, Inc. stock logo
CYRX
CryoPort
N/A
2.08
1.98
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
N/A
4.57
4.57
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
0.73
1.79
1.32
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
N/A
10.14
10.14

Institutional Ownership

CompanyInstitutional Ownership
CryoPort, Inc. stock logo
CYRX
CryoPort
92.90%
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
78.63%
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
90.60%
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
50.71%

Insider Ownership

CompanyInsider Ownership
CryoPort, Inc. stock logo
CYRX
CryoPort
9.50%
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
12.69%
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
2.80%
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
41.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
CryoPort, Inc. stock logo
CYRX
CryoPort
73850.65 million45.84 millionOptionable
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
48567.34 million58.80 millionOptionable
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
7175.60 million5.44 millionNot Optionable
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
130127.25 million74.95 millionOptionable

Recent News About These Companies

Nautilus Biotechnology to Report Third Quarter 2026 Financial Results on October 27
 |  quiverquant.comQ
Nautilus Biotechnology to Announce Third Quarter 2026 Financial Results on October 27, 2026
 |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/15/3381545/0/en/nautilus-biotechnology-to-announce-third-quarter-2026-financial-results-on-october-27-2026.html
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Stock Has Consensus Price Target of $3.83 According to Analysts
October 7, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31094613
Stock Traders Buy High Volume of Call Options on Nautilus Biotechnology (NASDAQ:NAUT)
October 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31087439
Nautilus Biotechnology Sees Unusually High Options Volume (NASDAQ:NAUT)
October 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/options-nautilus-biotechnology-sees-unusually-high-options-volume-nasdaq-naut-2026-10-05/
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Stock Has Average Price Target of $3.83
October 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-nautilus-biotechnology-inc-nasdaq-naut-stock-has-average-price-target-of-383-2026-10-02/
Zacks Research Upgrades Nautilus Biotechnology (NASDAQ:NAUT) to "Hold"
October 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-zacks-research-upgrades-nautilus-biotechnology-nasdaq-naut-to-hold-2026-10-02/
Voyager Will Take Center Stage In Nautilus' Commercial Push
October 1, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4951383-voyager-stock-will-take-center-stage-in-nautilus-commercial-push
Nautilus Biotechnology (NASDAQ:NAUT) Raised to "Strong-Buy" at Roth Capital
September 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-nautilus-biotechnology-nasdaq-naut-raised-to-strong-buy-at-roth-capital-2026-09-30/
Roth Capital initiates coverage of Nautilus Biotechnology with buy
September 29, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/roth-capital-initiates-coverage-of-nautilus-biotechnology-with-buy/ar-AA2deU20
Why Nautilus Biotechnology, Inc.’s (NAUT) Stock Is Down 10.27%
September 10, 2026  |  aaii.comA
Nautilus Biotechnology Analyst Price Targets
September 10, 2026  |  benzinga.comhttps://www.benzinga.com/quote/NAUT/price-targets
Leerink Partners initiates coverage of Nautilus Biotechnology with outperform
September 10, 2026  |  msn.comhttps://www.msn.com/en-us/technology/biotechnology/leerink-partners-initiates-coverage-of-nautilus-biotechnology-with-outperform/ar-AA2bVKvc
Nautilus Biotechnology Reveals Tau Proteoform Insights In Nature Methods Publication
September 4, 2026  |  rttnews.comhttps://www.rttnews.com/3688626/nautilus-biotechnology-reveals-tau-proteoform-insights-in-nature-methods-publication.aspx
Nature Methods Publication Reveals Deep Insights into Functional Biology through First-of-its-Kind Quantification of Tau Proteoforms
September 4, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/04/3356532/0/en/nature-methods-publication-reveals-deep-insights-into-functional-biology-through-first-of-its-kind-quantification-of-tau-proteoforms.html
Shifting its Strategy, Nautilus Sees Targeted Protein Assay Market as Multi-Billion Dollar Opportunity
August 31, 2026  |  genomeweb.comG
Nautilus Biotechnology: Contrarian Proteoformics Play After The Recent Pullback
August 3, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4929390-nautilus-biotechnology-contrarian-proteoformics-play-after-the-recent-pullback
Nautilus Biotechnology Inc (NAUT) Q2 2026 Earnings Call Highlights: Strategic Shifts and ...
July 29, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/nautilus-biotechnology-inc-naut-q2-210150434.html
Nautilus outlines cash runway into Q1 2028 while shifting R&D toward ~20 proteoform assays by mid-2028
July 29, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4619629-nautilus-outlines-cash-runway-into-q1-2028-while-shifting-r-and-d-toward-20-proteoform-assays
Nautilus Biotechnology Reports Second Quarter 2026 Financial Results
July 28, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/nautilus-biotechnology-reports-second-quarter-2026-financial-results-1036371698
Nautilus Biotechnology to Announce Second Quarter 2026 Financial Results on July 28, 2026
July 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/08/3324019/0/en/nautilus-biotechnology-to-announce-second-quarter-2026-financial-results-on-july-28-2026.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

CryoPort stock logo

CryoPort NASDAQ:CYRX

$16.82 +0.19 (+1.11%)
As of 11:32 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

Ginkgo Bioworks stock logo

Ginkgo Bioworks NYSE:DNA

$11.42 -0.12 (-1.00%)
As of 11:33 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Mesa Laboratories stock logo

Mesa Laboratories NASDAQ:MLAB

$127.86 +1.70 (+1.35%)
As of 11:33 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. The Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. The Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems, offered under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.

Nautilus Biotechnology stock logo

Nautilus Biotechnology NASDAQ:NAUT

$2.04 -0.12 (-5.32%)
As of 11:32 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas